From: Focal cryosurgical ablation of the prostate: a single institute’s perspective
Authors, dates | No. of pts | Follow-up years | Biochemical failure definition | Biochemical disease -free survival | Biopsy proven ipsilateral disease | Potency | Continence | Voiding symptoms |
---|---|---|---|---|---|---|---|---|
Lambert et al., 2007[11] | 25 | 2.3 (median) | ASTRO criteria | 84% (PSA Nadir >50%) | 4% | 71% | 100% | N/A |
Ellis et al., 2007[12] | 60 | 1.3 (mean) | ASTRO criteria | 80% (ASTRO) | 1.7% | 70.6% @ 1yr | 96.4% | N/A |
Onik et al., 2008[7] | 48 | 4.5 (mean) | ASTRO criteria | 94% (ASTRO) | 0% | 90% | 100% | N/A |
Truesdale et al., 2010[13] | 77 | 2 (median) | Phoenix criteria | 73% | 4% | N/A | N/A | N/A |
Ward et al., 2012[14] | 1160 | 1.8 (mean) | ASTRO criteria | 75.7% (ASTRO) @ 3yr | 3.7% (Unsure Laterality) | 58.1% | 98.4% | 1.1%^ |
Bahn et al., 2012[2] | 73 | 3.7 (median) | ASTRO criteria | N/A | 1% | 86% | 100% | N/A |
Present Study | 26 | 1.6 (mean) | 0.5 ng/ml over nadir[8] | 88% | 0% | 73%* | 100% | 4%^ |